Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Andrea Moser

Physician Assistant Oklahoma City, OK Physician Assistant

NPI 1558332981 CMS profile 10906297

6205 N Santa Fe Ave Ste 200, Oklahoma City, OK 73118

Open in the dashboard

General payments

$9,333

431 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrea Moser of Oklahoma City, OK is reported in the CMS Open Payments database as having received $9,333 across 431 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,073 165
2024 General $2,286 106
2023 General $2,257 104
2022 General $1,556 53
2021 General $162 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrea Moser
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Andrea Moser were reported at $3,073. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Andrea Moser Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $162 $132 $37–$438 $132
2022 $1,556 $155 $48–$522 $149
2023 $2,257 $167 $52–$557 $160
2024 $2,286 $178 $55–$600 $164
2025 $3,073 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Corcept Therapeutics $1,070 45 payments
  2. Dexcom, Inc. $962 45 payments
  3. Medtronic, Inc. $899 13 payments
  4. Lilly USA, LLC $797 44 payments
  5. Xeris Pharmaceuticals, Inc. $616 34 payments
  6. Novo Nordisk Inc $597 31 payments
  7. Abbott Laboratories $510 20 payments
  8. Sanofi-Aventis U.S. LLC $488 24 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $408 24 payments
  10. Tandem Diabetes Care, Inc. $344 15 payments
  11. Other $2,642 136 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,032 427 payments
  2. Travel and Lodging $231 2 payments
  3. Gift $59 1 payment
  4. Education $10 1 payment
Products named General payments · program years 2021–2025
  1. Korlym $1,070 45 payments
  2. Dexcom G6 Transmitter $800 42 payments
  3. INPEN SMART INSULIN DELIVERY SYSTEM $560 8 payments
  4. RYBELSUS $479 23 payments
  5. FreeStyle Libre 3 $450 17 payments
  6. Kerendia $408 24 payments
  7. MOUNJARO $383 20 payments
  8. t:slim X2 Insulin Pump with Control-IQ $344 15 payments
  9. Ozempic $325 20 payments
  10. MINIMED 780G $323 4 payments
  11. Other $5,405 284 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 67 drugs

Part D claims

4,180

Median for Physician Assistant: 241

Drug cost

$3,007,229

Median for Physician Assistant: $4,110

Branded share of claims

71.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 393 $655,436
Mounjaro Tirzepatide Brand 306 $546,610
Jardiance Empagliflozin Brand 365 $439,257
Tresiba Flextouch U-200 Insulin Degludec Brand 228 $269,446
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 76 $133,989
Farxiga Dapagliflozin Propanediol Brand 92 $107,818
Trulicity Dulaglutide Brand 68 $91,705
Fiasp Flextouch Insulin Aspart (Niacinamide) Brand 61 $72,070
Lyumjev Kwikpen U-100 Insulin Lispro-Aabc Brand 58 $61,699
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 29 $48,544

The 10 drugs with the highest cost, of 67 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$47,301

Medicare's payments for the services billed

Medicare patients

286

Average age 70

Services billed

1,259

159 women, 127 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 41%
Chronic kidney disease 38%
Heart failure 22%
Depression 22%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
  • Corcept Therapeutics $411
$411 — —
JARDIANCE
  • Lilly USA, LLC $108
  • Boehringer Ingelheim Pharmaceuticals, Inc. $33
$141 365 —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $93
$93 30 —
RYBELSUS
  • Novo Nordisk Inc $86
$86 15 —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $85
$85 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

431 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record